Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page
- Check6 days agoChange DetectedThe study record now shows recruitment has ended, indicating the trial is not enrolling any more participants. Added navigation/help items (How to Read a Study Record, Common Questions, How to Join a Study) and a site revision label (Revision: v3.6.0); the header formatting around Intervention/Treatment was updated.SummaryDifference0.6%

- Check13 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5. This indicates a behind-the-scenes update to the study page's software or content management system.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4. This indicates a minor patch to the page.SummaryDifference0.1%

- Check56 days agoChange DetectedThis updates the ClinicalTrials.gov page’s visible revision/version label from v3.5.2 to v3.5.3 without changing any underlying study details.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No visible changes to study content or page functionality.SummaryDifference0.1%

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.